Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors IND-enabling studies ongoing with IND submission on track for first half of 2027 WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical-stage biotechnol